ClinicalTrials.gg
CompletedNCT00758524Updated Jul 6, 2021Results posted

A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension

A Phase 2 interventional study of LCI699 and Eplerenone in Essential Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-07-06.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
628
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Essential Hypertension by Novartis — none open to participants now, none under way, none of them phase 3. Essential Hypertension · Novartis.

Enrollment
10th of 25
628 · median 506
Started
2008
with 4 others
Phase 2
3 of 27
none open now
Registered
9th of 27
by date

Among the 27 studies in Essential Hypertension by Novartis, this one is the 10th largest by enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2008, is one of 3 in phase 2, and was the 9th registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

None of the 27 studies in Essential Hypertension by Novartis is open now. The open studies under Essential Hypertension, anywhere →

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 27 studies in Essential Hypertension by Novartis as a file.
02

Study summary

This study was a proof-of-efficacy, dose finding study of LCI699 in participants with mild-to-moderate uncomplicated essential hypertension in order to assess the blood pressure (BP) lowering effect, safety and tolerability of LCI699 as compared to placebo and eplerenone.

03

Conditions studied

  • Essential Hypertension

Keywords

  • Essential hypertension
  • Phase 2 study
  • Antihypertensive agent
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and non-fertile females.
  • 18-75 years inclusive.
  • Participants with mild-to-moderate uncomplicated essential hypertension.

Exclusion criteria

Exclusion Criteria:

  • All women of child bearing potential.
  • Female participants on hormone replacement therapy.
  • Severe hypertension.
  • History or evidence of a secondary form of hypertension.
  • Known moderate or malignant retinopathy.
  • History of angina pectoris, myocardial infarction, coronary bypass surgery,ischemic heart disease, surgical or percutaneous arterial intervention of any kind (coronary, carotid or peripheral vessels), stroke, (TIA), carotid artery stenosis, aortic aneurysm or peripheral arterial disease.
  • Type 1 or type 2 diabetes mellitus.
  • valvular heart disease.
  • Congestive heart failure ( [NYHA] class II-IV).
  • Cardiac electrical abnormalities indicating significant risk of safety for participant taking part in the study.
  • History of of any organ system, treated or untreated, within the past 5 years.
  • Liver disease such as cirrhosis or chronic active hepatitis.
  • Any surgical or medical conditions that may significantly alter the absorption, distribution, metabolism or excretion of any drug substance
  • Any surgical or medical conditions, not identified in the protocol that in the opinion of the investigator or the monitor, place the participant at higher risk from his/her participation in the study, or is likely to prevent the participant from complying with the requirements of the study or completing the trial period.
  • Participant unwilling or not able to discontinue safely the use of current antihypertensive medications during the study period
  • Any or history of to any of the study drugs or to drugs with similar chemical structures.
  • Chronic oral or parenteral treatment.
  • Treatment with potassium supplement or potassium sparing diuretics.
  • Treatment with potent cytochrome P450 3A4 () inhibitors during the study period.
  • Use of other drugs at Visit 1, or within 30 days or 5 half-lives of Visit 1, whichever is longer, unless local health authority guidelines mandate a longer period.
  • Serum potassium > 5.2 milliequivalents per liter (mEq/L) or \< 3.5 mEq/L at Visit 1.
  • Serum sodium \< 132 mEq/L at Visit 1.
  • (ALT) or alanine aminotransferase (AST) > 2 times the (ULN) at Visit 1.
  • (total) > 1.5 x ULN at Visit 1.
  • Modification of diet in renal disease estimated (MDRD eGFR) \< 60 milliliters per minute (ml/min)/1.73 m\^2 at Visit 1.
  • Other clinically significant laboratory abnormalities, confirmed by repeat measurements, at Visit 1.
  • History of active substance abuse (including alcohol).
  • Participants with night-shift employment.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
628 participants (actual)

Study arms

  • Experimental
    Core Period: LCI699 0.25 mg QD

    Participants received LCI699 0.25 mg capsules, orally, once daily (QD), with or without food for up to 8 weeks.

    Drug: LCI699

  • Experimental
    Core Period: LCI699 0.5 mg QD

    Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 8 weeks.

    Drug: LCI699

  • Experimental
    Core Period: LCI699 1.0 mg QD

    Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 8 weeks.

    Drug: LCI699

  • Experimental
    Core Period: LCI699 0.5 mg BID

    Participants received LCI699 0.5 mg capsules, orally, twice daily (BID), with or without food for up to 8 weeks.

    Drug: LCI699

  • Active comparator
    Core Period: Eplerenone 50 mg BID

    Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 8 weeks.

    Drug: Eplerenone

  • Placebo comparator
    Core Period: Placebo

    Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 8 weeks.

    Drug: LCI699-matching Placebo · Drug: Eplerenone-matching Placebo

  • Experimental
    Withdrawal Period: LCI699 0.25 mg QD

    Participants received LCI699 0.25 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).

    Drug: LCI699

  • Placebo comparator
    Withdrawal Period: LCI699 0.25 mg QD Placebo

    Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).

    Drug: LCI699-matching Placebo

  • Experimental
    Withdrawal Period: LCI699 0.5 mg QD

    Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).

    Drug: LCI699

  • Placebo comparator
    Withdrawal Period: LCI699 0.5 mg QD Placebo

    Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).

    Drug: LCI699-matching Placebo

  • Experimental
    Withdrawal Period: LCI699 1.0 mg QD

    Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).

    Drug: LCI699

  • Placebo comparator
    Withdrawal Period: LCI699 1.0 mg QD Placebo

    Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).

    Drug: LCI699-matching Placebo

  • Experimental
    Withdrawal Period: LCI699 0.5 mg BID

    Participants received LCI699 0.5 mg capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).

    Drug: LCI699

  • Placebo comparator
    Withdrawal Period: LCI699 0.5 mg BID Placebo

    Participants received LCI699 matching placebo capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).

    Drug: LCI699-matching Placebo

  • Active comparator
    Withdrawal Period: Eplerenone 50 mg BID

    Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).

    Drug: Eplerenone

  • Placebo comparator
    Withdrawal Period: Eplerenone 50 mg BID Placebo

    Participants received eplerenone matching placebo capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).

    Drug: Eplerenone-matching Placebo

  • Placebo comparator
    Withdrawal Period: Placebo

    Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 1 week (Week 8 to Week 9).

    Drug: LCI699-matching Placebo · Drug: Eplerenone-matching Placebo

Interventions

  • DrugLCI699

    LCI699 oral capsules

  • Eplerenone oral capsules

  • DrugLCI699-matching Placebo

    LCI699-matching placebo oral capsules

  • DrugEplerenone-matching Placebo

    Eplerenone-matching placebo oral capsules

06

What researchers measure

Primary outcomes

  1. Core Period: Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8 Last Observation Carried Forward (LOCF), as Measured by Office Blood Pressure (OBP)

    Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSDBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and region as factors and baseline MSDBP level as a covariate.

    Time frame: Baseline, Week 8

Secondary outcomes

  1. Core Period: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8 LOCF, as Measured by OBP

    Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSSBP was analyzed using an ANCOVA with treatment and region as factors and baseline MSSBP levels as a covariate.

    Time frame: Baseline, Week 8

  2. Core Period: Number of Participants With Adverse Event (AEs), Serious Adverse Events (SAEs), and Deaths

    An AE was an adverse medical event which occurs in a participant of the study and which is not necessarily in a causal relationship with the treatment the participant receives. SAEs were AEs leading to death, are life-threatening, require hospitalizations or prolongation of hospitalizations, represent an innate malformation or a congenital abnormality.

    Time frame: AEs: From start of the study drug treatment up to 8 weeks; SAE: From signing of the informed consent up to 8 weeks

  3. Core Period: Dose Response Relationship of LCI699 as Measured by Change From Baseline in MSDBP at Week 8

    Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSDBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and region as factors and baseline MSDBP level as a covariate.

    Time frame: Baseline, Week 8

  4. Core Period: Dose Response Relationship of LCI699 as Measured by Change From Baseline in MSSBP at Week 8

    Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSSBP was analyzed using an ANCOVA with treatment and region as factors and baseline MSSBP levels as a covariate.

    Time frame: Baseline, Week 8

  5. Core Period: Change From Baseline in Mean 24 Hour Ambulatory SBP at Week 8 as Measured by Ambulatory Blood Pressure Monitoring (ABPM)

    An ABPM measured a participant's BP over a 24-hour period readings using an automated validated monitoring device from Baseline to Week 8. The 24-hour SBP was calculated by taking the mean of all ambulatory SBP readings for the 24-hour period.

    Time frame: Baseline, Week 8

  6. Core Period: Change From Baseline in Mean 24 Hour Ambulatory DBP at Week 8, as Measured by ABPM

    An ABPM measured a participant's BP over a 24-hour period readings using an automated validated monitoring device from Baseline to Week 8. The 24-hour DBP was calculated by taking the mean of all ambulatory DBP readings for the 24-hour period.

    Time frame: Baseline, Week 8

  7. Core Period: Trough to Hour Ratio for Change From Baseline in 24-hour Mean Ambulatory DBP at Week 8

    Trough to peak ratios were derived from an ANCOVA model containing treatment, region, hour, treatment by hour interaction as factors with Baseline as a covariate.

    Time frame: Baseline, every hour up to 24 hours post-dose at Week 8

  8. Core Period: Trough to Hour Ratio for Change From Baseline in 24-hour Mean Ambulatory SBP at Week 8

    Trough to peak ratios were derived from an ANCOVA model containing treatment, region, hour, treatment by hour interaction as factors with Baseline as a covariate.

    Time frame: Baseline, every hour up to 24 hours post-dose at Week 8

  9. Core Period: Change From Baseline in Plasma Aldosterone Levels at Week 8

    Change from baseline was analyzed using plasma aldosterone values measured at Baseline and Week 8.

    Time frame: Baseline, Week 8

  10. Core Period: Percentage of Participants With a MSDBP Response and MSDBP Control at Week 8 LOCF

    MSDBP response was defined as the percentage of participants with a MSDBP \<90 mmHg or a \>=10 mmHg reduction from Baseline. MSDBP control was defined as the percentage of participants with a MSDBP \<90 mmHg.

    Time frame: Baseline, Week 8

  11. Core Period: Percentage of Participants With a MSSBP Response and MSSBP Control at Week 8 LOCF

    MSSBP response was defined as the percentage of participants with a MSSBP \<140 mmHg or a \>=20 mmHg reduction from baseline reduction from baseline. MSSBP control was defined as the percentage of participants with a MSSBP \<140 mmHg.

    Time frame: Baseline, Week 8

  12. Core Period: Change From Baseline in Plasma Cortisol Levels by Adrenocorticotropic Hormone (ACTH) Stimulation Test

    The ACTH stimulation cortisol test was a standard procedure to measure the ability of adrenal cortex to respond to exogenous ACTH and directly assess the adrenal reserve. Serum cortisol concentrations at 1 hour after injection were measured to assess the maximum stimulated cortisol level achieved. Potential adrenal suppression was indicated if the serum cortisol concentration was \<500 nanomoles per liter (nmol/L) at 1 hour after the injection.

    Time frame: Baseline, 1 hour post-dose at Week 8

  13. Withdrawal Period: Change From Week 8 to Week 9 in MSDBP at Week 9, as Measured by OBP

    Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSDBP was calculated comparing the Week 9 readings to the readings taken at Week 8 (Baseline). The change from Week 8 to week 9 in MSDBP was analyzed using an ANCOVA with treatment and region as factors and Week 8 MSDBP level as a covariate.

    Time frame: From Week 8 to Week 9

  14. Withdrawal Period: Change From Week 8 to Week 9 in MSSBP at Week 9 as Measured by OBP

    Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSSBP was calculated comparing the Week 9 readings to the readings taken at Week 8 (Baseline). The change from Week 8 to week 9 in MSSBP was analyzed using an ANCOVA with treatment and region as factors and Week 8 MSSBP level as a covariate.

    Time frame: From Week 8 to Week 9

07

Results

Posted Jul 6, 2021

Participant flow

Participants took part at 84 investigative sites in Argentina, Australia, France, Germany, Netherlands, Romania, Spain, Sweden, and the United States from 11 September 2008 to 02 July 2009.

Core Period (Week 0 to Week 8)
Participant flow — Core Period (Week 0 to Week 8)
MilestoneCore Period: LCI699 0.25 mg QDCore Period: LCI699 0.5 mg QDCore Period: LCI699 1.0 mg QDCore Period: LCI699 0.5 mg BIDCore Period: Eplerenone 50 mg BIDCore Period: PlaceboWithdrawal Period: LCI699 0.25 mg QDWithdrawal Period: LCI699 0.25 mg QD PlaceboWithdrawal Period: LCI699 0.5 mg QDWithdrawal Period: LCI699 0.5 mg QD PlaceboWithdrawal Period: LCI699 1.0 mg QDWithdrawal Period: LCI699 1.0 mg QD PlaceboWithdrawal Period: LCI699 0.5 mg BIDWithdrawal Period: LCI699 0.5 mg BID PlaceboWithdrawal Period: Eplerenone 50 mg BIDWithdrawal Period: Eplerenone 50 mg BID PlaceboWithdrawal Period: Placebo
Started92888697847700000000000
Treated92878797847600000000000
Completed84817790756700000000000
Not completed879791000000000000
Withdrew: Lack of efficacy32403500000000000
Withdrew: Withdrawal by subject30231300000000000
Withdrew: Adverse event21132100000000000
Withdrew: Lost to follow-up02102100000000000
Withdrew: Administrative problems00110000000000000
Withdrew: Abnormal laboratory values00001000000000000
Withdrew: Abnormal test procedure results01000000000000000
Withdrew: Reason not specified01000000000000000
Withdrawal Period (Week 8 to Week 9)
Participant flow — Withdrawal Period (Week 8 to Week 9)
MilestoneCore Period: LCI699 0.25 mg QDCore Period: LCI699 0.5 mg QDCore Period: LCI699 1.0 mg QDCore Period: LCI699 0.5 mg BIDCore Period: Eplerenone 50 mg BIDCore Period: PlaceboWithdrawal Period: LCI699 0.25 mg QDWithdrawal Period: LCI699 0.25 mg QD PlaceboWithdrawal Period: LCI699 0.5 mg QDWithdrawal Period: LCI699 0.5 mg QD PlaceboWithdrawal Period: LCI699 1.0 mg QDWithdrawal Period: LCI699 1.0 mg QD PlaceboWithdrawal Period: LCI699 0.5 mg BIDWithdrawal Period: LCI699 0.5 mg BID PlaceboWithdrawal Period: Eplerenone 50 mg BIDWithdrawal Period: Eplerenone 50 mg BID PlaceboWithdrawal Period: Placebo
Started0000004638443741374545393666
Randomized withdrawal set0000004538433741364544393667
Completed0000004538423741374545393666
Not completed00000010200000000
Withdrew: Unsatisfactory therapeutic effect00000000200000000
Withdrew: Lost to follow-up00000010000000000

Outcome measures

PrimaryCore Period: Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8 Last Observation Carried Forward (LOCF), as Measured by Office Blood Pressure (OBP)

Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSDBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and region as factors and baseline MSDBP level as a covariate.

Time frame:
Baseline, Week 8
Reported as:
Mean · mm Hg
Core Period: Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8 Last Observation Carried Forward (LOCF), as Measured by Office Blood Pressure (OBP)
mm HgCore Period: LCI699 0.25 mg QDCore Period: LCI699 0.5 mg QDCore Period: LCI699 1.0 mg QDCore Period: LCI699 0.5 mg BIDCore Period: Eplerenone 50 mg BIDCore Period: Placebo
Core Period: Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8 Last Observation Carried Forward (LOCF), as Measured by Office Blood Pressure (OBP)-4.47 ± 0.60-5.50 ± 0.57-7.11 ± 0.88-4.25 ± 0.95-7.49 ± 0.97-3.22 ± 0.87
SecondaryCore Period: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8 LOCF, as Measured by OBP

Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSSBP was analyzed using an ANCOVA with treatment and region as factors and baseline MSSBP levels as a covariate.

Time frame:
Baseline, Week 8
Reported as:
Mean · mm Hg
Core Period: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8 LOCF, as Measured by OBP
mm HgCore Period: LCI699 0.25 mg QDCore Period: LCI699 0.5 mg QDCore Period: LCI699 1.0 mg QDCore Period: LCI699 0.5 mg BIDCore Period: Eplerenone 50 mg BIDCore Period: Placebo
Core Period: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8 LOCF, as Measured by OBP-9.00 ± 1.40-10.69 ± 0.98-11.93 ± 1.44-9.10 ± 1.45-13.31 ± 1.48-2.93 ± 1.68
SecondaryCore Period: Number of Participants With Adverse Event (AEs), Serious Adverse Events (SAEs), and Deaths

An AE was an adverse medical event which occurs in a participant of the study and which is not necessarily in a causal relationship with the treatment the participant receives. SAEs were AEs leading to death, are life-threatening, require hospitalizations or prolongation of hospitalizations, represent an innate malformation or a congenital abnormality.

Time frame:
AEs: From start of the study drug treatment up to 8 weeks; SAE: From signing of the informed consent up to 8 weeks
Reported as:
Count of participants · Participants
Core Period: Number of Participants With Adverse Event (AEs), Serious Adverse Events (SAEs), and Deaths
ParticipantsCore Period: LCI699 0.25 mg QDCore Period: LCI699 0.5 mg QDCore Period: LCI699 1.0 mg QDCore Period: LCI699 0.5 mg BIDCore Period: Eplerenone 50 mg BIDCore Period: Placebo
AEs232224272623
SAEs100001
Deaths000000
SecondaryCore Period: Dose Response Relationship of LCI699 as Measured by Change From Baseline in MSDBP at Week 8

Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSDBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and region as factors and baseline MSDBP level as a covariate.

Time frame:
Baseline, Week 8
Reported as:
Mean · mm Hg
Core Period: Dose Response Relationship of LCI699 as Measured by Change From Baseline in MSDBP at Week 8
mm HgCore Period: LCI699 0.25 mg QDCore Period: LCI699 0.5 mg QDCore Period: LCI699 1.0 mg QDCore Period: LCI699 0.5 mg BID
Core Period: Dose Response Relationship of LCI699 as Measured by Change From Baseline in MSDBP at Week 8-4.47 ± 0.60-5.50 ± 0.57-7.11 ± 0.88-4.25 ± 0.95
SecondaryCore Period: Dose Response Relationship of LCI699 as Measured by Change From Baseline in MSSBP at Week 8

Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSSBP was analyzed using an ANCOVA with treatment and region as factors and baseline MSSBP levels as a covariate.

Time frame:
Baseline, Week 8
Reported as:
Mean · mm Hg
Core Period: Dose Response Relationship of LCI699 as Measured by Change From Baseline in MSSBP at Week 8
mm HgCore Period: LCI699 0.25 mg QDCore Period: LCI699 0.5 mg QDCore Period: LCI699 1.0 mg QDCore Period: LCI699 0.5 mg BID
Core Period: Dose Response Relationship of LCI699 as Measured by Change From Baseline in MSSBP at Week 8-9.00 ± 1.40-10.69 ± 0.98-11.93 ± 1.44-9.10 ± 1.45
SecondaryCore Period: Change From Baseline in Mean 24 Hour Ambulatory SBP at Week 8 as Measured by Ambulatory Blood Pressure Monitoring (ABPM)

An ABPM measured a participant's BP over a 24-hour period readings using an automated validated monitoring device from Baseline to Week 8. The 24-hour SBP was calculated by taking the mean of all ambulatory SBP readings for the 24-hour period.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · mm Hg
Core Period: Change From Baseline in Mean 24 Hour Ambulatory SBP at Week 8 as Measured by Ambulatory Blood Pressure Monitoring (ABPM)
mm HgCore Period: LCI699 0.25 mg QDCore Period: LCI699 0.5 mg QDCore Period: LCI699 1.0 mg QDCore Period: LCI699 0.5 mg BIDCore Period: Eplerenone 50 mg BIDCore Period: Placebo
Core Period: Change From Baseline in Mean 24 Hour Ambulatory SBP at Week 8 as Measured by Ambulatory Blood Pressure Monitoring (ABPM)-7.15 ± 1.20-4.90 ± 1.22-7.73 ± 1.13-6.18 ± 1.14-10.52 ± 1.251.11 ± 1.30
SecondaryCore Period: Change From Baseline in Mean 24 Hour Ambulatory DBP at Week 8, as Measured by ABPM

An ABPM measured a participant's BP over a 24-hour period readings using an automated validated monitoring device from Baseline to Week 8. The 24-hour DBP was calculated by taking the mean of all ambulatory DBP readings for the 24-hour period.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · mm Hg
Core Period: Change From Baseline in Mean 24 Hour Ambulatory DBP at Week 8, as Measured by ABPM
mm HgCore Period: LCI699 0.25 mg QDCore Period: LCI699 0.5 mg QDCore Period: LCI699 1.0 mg QDCore Period: LCI699 0.5 mg BIDCore Period: Eplerenone 50 mg BIDCore Period: Placebo
Core Period: Change From Baseline in Mean 24 Hour Ambulatory DBP at Week 8, as Measured by ABPM-4.03 ± 0.91-2.44 ± 0.92-4.96 ± 0.86-2.75 ± 0.86-6.03 ± 0.941.03 ± 0.99
SecondaryCore Period: Trough to Hour Ratio for Change From Baseline in 24-hour Mean Ambulatory DBP at Week 8

Trough to peak ratios were derived from an ANCOVA model containing treatment, region, hour, treatment by hour interaction as factors with Baseline as a covariate.

Time frame:
Baseline, every hour up to 24 hours post-dose at Week 8
Reported as:
Least squares mean · ratio
Core Period: Trough to Hour Ratio for Change From Baseline in 24-hour Mean Ambulatory DBP at Week 8
ratioCore Period: LCI699 0.25 mg QDCore Period: LCI699 0.5 mg QDCore Period: LCI699 1.0 mg QDCore Period: LCI699 0.5 mg BIDCore Period: Eplerenone 50 mg BIDCore Period: Placebo
Week 8, Hour 13.91 ± 1.4662.95 ± 1.5410.27 ± 1.3893.87 ± 1.4040.17 ± 1.5447.11 ± 1.588
Week 8, Hour 21.44 ± 1.4521.85 ± 1.4880.17 ± 1.3973.44 ± 1.381-1.65 ± 1.5296.28 ± 1.586
Week 8, Hour 31.16 ± 1.4771.13 ± 1.502-0.36 ± 1.3874.01 ± 1.369-2.42 ± 1.5284.99 ± 1.585
Week 8, Hour 40.51 ± 1.4522.91 ± 1.4880.35 ± 1.3862.64 ± 1.378-1.39 ± 1.5417.02 ± 1.584
Week 8, Hour 51.11 ± 1.463-0.02 ± 1.513-1.69 ± 1.3851.45 ± 1.377-2.91 ± 1.5144.31 ± 1.584
Week 8, Hour 6-1.18 ± 1.451-2.36 ± 1.487-3.01 ± 1.3861.20 ± 1.367-4.86 ± 1.5131.82 ± 1.585
Week 8, Hour 7-1.85 ± 1.463-0.95 ± 1.487-2.63 ± 1.4061.21 ± 1.366-3.70 ± 1.5133.62 ± 1.599
Week 8, Hour 8-3.01 ± 1.464-1.38 ± 1.487-2.43 ± 1.3962.09 ± 1.366-2.30 ± 1.5142.65 ± 1.616
Week 8, Hour 9-1.24 ± 1.464-0.07 ± 1.487-2.25 ± 1.3863.27 ± 1.366-2.81 ± 1.5153.30 ± 1.600
Week 8, Hour 10-0.59 ± 1.4522.60 ± 1.487-1.65 ± 1.3850.49 ± 1.378-2.43 ± 1.5153.86 ± 1.585
Week 8, Hour 11-1.02 ± 1.4511.72 ± 1.487-1.54 ± 1.3861.54 ± 1.367-1.93 ± 1.5142.38 ± 1.585
Week 8, Hour 12-1.60 ± 1.4512.53 ± 1.487-3.10 ± 1.385-1.06 ± 1.367-3.20 ± 1.5273.24 ± 1.584
Week 8, Hour 13-4.32 ± 1.451-1.20 ± 1.487-5.31 ± 1.385-1.45 ± 1.366-5.35 ± 1.5131.52 ± 1.584
Week 8, Hour 14-6.47 ± 1.451-3.29 ± 1.487-7.38 ± 1.385-2.96 ± 1.376-7.64 ± 1.513-0.90 ± 1.584
Week 8, Hour 15-8.34 ± 1.452-5.82 ± 1.488-8.89 ± 1.386-6.10 ± 1.377-9.03 ± 1.527-1.01 ± 1.586
Week 8, Hour 16-8.92 ± 1.465-8.37 ± 1.491-10.50 ± 1.387-9.54 ± 1.369-12.55 ± 1.528-1.61 ± 1.587
Week 8, Hour 17-10.26 ± 1.454-10.99 ± 1.492-12.71 ± 1.398-10.38 ± 1.380-12.88 ± 1.516-4.20 ± 1.604
Week 8, Hour 18-10.68 ± 1.456-11.73 ± 1.492-11.88 ± 1.389-11.85 ± 1.379-13.49 ± 1.529-6.89 ± 1.587
Week 8, Hour 19-10.13 ± 1.456-10.12 ± 1.493-9.74 ± 1.388-10.78 ± 1.369-10.13 ± 1.517-5.84 ± 1.587
Week 8, Hour 20-10.73 ± 1.454-8.06 ± 1.504-10.43 ± 1.408-10.49 ± 1.369-10.47 ± 1.516-5.21 ± 1.602
Week 8, Hour 21-9.31 ± 1.453-7.68 ± 1.489-9.66 ± 1.386-8.22 ± 1.377-10.51 ± 1.514-4.12 ± 1.586
Week 8, Hour 22-7.90 ± 1.452-4.93 ± 1.487-5.37 ± 1.385-6.35 ± 1.386-7.60 ± 1.513-1.09 ± 1.585
Week 8, Hour 23-4.94 ± 1.475-1.93 ± 1.487-1.18 ± 1.385-2.67 ± 1.377-5.54 ± 1.5131.82 ± 1.599
Week 8, Hour 24-0.21 ± 1.4771.45 ± 1.5010.29 ± 1.3971.36 ± 1.370-2.78 ± 1.5291.98 ± 1.617
SecondaryCore Period: Trough to Hour Ratio for Change From Baseline in 24-hour Mean Ambulatory SBP at Week 8

Trough to peak ratios were derived from an ANCOVA model containing treatment, region, hour, treatment by hour interaction as factors with Baseline as a covariate.

Time frame:
Baseline, every hour up to 24 hours post-dose at Week 8
Reported as:
Least squares mean · ratio
Core Period: Trough to Hour Ratio for Change From Baseline in 24-hour Mean Ambulatory SBP at Week 8
ratioCore Period: LCI699 0.25 mg QDCore Period: LCI699 0.5 mg QDCore Period: LCI699 1.0 mg QDCore Period: LCI699 0.5 mg BIDCore Period: Eplerenone 50 mg BIDCore Period: Placebo
Week 8, Hour 1-0.54 ± 1.7670.09 ± 1.859-4.51 ± 1.674-1.42 ± 1.690-5.33 ± 1.8638.23 ± 1.915
Week 8, Hour 2-1.59 ± 1.7520.15 ± 1.795-3.56 ± 1.685-0.57 ± 1.663-5.90 ± 1.8446.48 ± 1.913
Week 8, Hour 3-2.11 ± 1.781-1.53 ± 1.811-4.86 ± 1.6720.91 ± 1.649-5.89 ± 1.8434.60 ± 1.912
Week 8, Hour 4-2.06 ± 1.752-1.18 ± 1.794-4.15 ± 1.6721.50 ± 1.661-5.12 ± 1.8594.68 ± 1.912
Week 8, Hour 5-4.29 ± 1.766-3.09 ± 1.825-3.47 ± 1.671-1.70 ± 1.660-7.22 ± 1.8262.78 ± 1.912
Week 8, Hour 6-4.21 ± 1.751-3.12 ± 1.794-5.88 ± 1.672-1.02 ± 1.648-7.91 ± 1.8261.42 ± 1.912
Week 8, Hour 7-4.95 ± 1.766-2.10 ± 1.794-5.40 ± 1.697-0.76 ± 1.649-8.70 ± 1.8262.25 ± 1.930
Week 8, Hour 8-5.28 ± 1.766-4.69 ± 1.794-5.30 ± 1.684-3.02 ± 1.649-8.06 ± 1.8273.76 ± 1.950
Week 8, Hour 9-3.98 ± 1.766-1.59 ± 1.795-4.78 ± 1.672-1.87 ± 1.649-7.46 ± 1.8282.39 ± 1.931
Week 8, Hour 10-3.69 ± 1.752-0.30 ± 1.794-3.40 ± 1.672-1.73 ± 1.662-7.35 ± 1.8282.54 ± 1.913
Week 8, Hour 11-2.47 ± 1.751-0.43 ± 1.795-4.22 ± 1.672-1.74 ± 1.649-5.75 ± 1.8273.51 ± 1.913
Week 8, Hour 12-5.19 ± 1.7520.73 ± 1.794-4.35 ± 1.671-3.92 ± 1.650-6.25 ± 1.8434.69 ± 1.912
Week 8, Hour 13-6.45 ± 1.751-2.30 ± 1.794-7.25 ± 1.671-4.05 ± 1.649-8.81 ± 1.8263.20 ± 1.912
Week 8, Hour 14-7.37 ± 1.751-5.68 ± 1.794-9.33 ± 1.671-6.12 ± 1.660-10.91 ± 1.8260.75 ± 1.912
Week 8, Hour 15-10.61 ± 1.752-8.28 ± 1.795-11.26 ± 1.672-9.78 ± 1.661-12.04 ± 1.8420.02 ± 1.912
Week 8, Hour 16-11.71 ± 1.767-10.01 ± 1.797-12.63 ± 1.672-13.03 ± 1.651-16.68 ± 1.843-0.33 ± 1.914
Week 8, Hour 17-13.71 ± 1.754-11.96 ± 1.799-15.46 ± 1.685-13.72 ± 1.664-19.59 ± 1.828-3.03 ± 1.933
Week 8, Hour 18-14.49 ± 1.756-14.37 ± 1.800-14.54 ± 1.675-15.60 ± 1.664-18.55 ± 1.844-6.35 ± 1.915
Week 8, Hour 19-13.78 ± 1.756-13.08 ± 1.801-12.85 ± 1.674-15.93 ± 1.652-15.49 ± 1.830-6.98 ± 1.914
Week 8, Hour 20-13.92 ± 1.756-13.22 ± 1.814-12.54 ± 1.699-15.47 ± 1.652-16.09 ± 1.829-6.53 ± 1.934
Week 8, Hour 21-14.33 ± 1.754-10.06 ± 1.797-12.78 ± 1.672-13.63 ± 1.662-15.34 ± 1.827-3.89 ± 1.914
Week 8, Hour 22-13.46 ± 1.752-8.35 ± 1.794-7.52 ± 1.671-10.55 ± 1.673-12.47 ± 1.826-0.94 ± 1.912
Week 8, Hour 23-7.88 ± 1.780-6.23 ± 1.794-5.77 ± 1.671-6.73 ± 1.661-9.02 ± 1.8262.18 ± 1.930
Week 8, Hour 24-3.16 ± 1.781-0.64 ± 1.810-3.45 ± 1.685-3.76 ± 1.651-8.90 ± 1.8440.70 ± 1.951
SecondaryCore Period: Change From Baseline in Plasma Aldosterone Levels at Week 8

Change from baseline was analyzed using plasma aldosterone values measured at Baseline and Week 8.

Time frame:
Baseline, Week 8
Reported as:
Mean · picomoles per liter (pmol/L)
Core Period: Change From Baseline in Plasma Aldosterone Levels at Week 8
picomoles per liter (pmol/L)Core Period: LCI699 0.25 mg QDCore Period: LCI699 0.5 mg QDCore Period: LCI699 1.0 mg QDCore Period: LCI699 0.5 mg BIDCore Period: Eplerenone 50 mg BIDCore Period: Placebo
Core Period: Change From Baseline in Plasma Aldosterone Levels at Week 8-21.5 ± 122-20.0 ± 156-9.9 ± 266-47.5 ± 170277.1 ± 429-28.8 ± 163
SecondaryCore Period: Percentage of Participants With a MSDBP Response and MSDBP Control at Week 8 LOCF

MSDBP response was defined as the percentage of participants with a MSDBP \<90 mmHg or a \>=10 mmHg reduction from Baseline. MSDBP control was defined as the percentage of participants with a MSDBP \<90 mmHg.

Time frame:
Baseline, Week 8
Reported as:
Number · percentage of participants
Core Period: Percentage of Participants With a MSDBP Response and MSDBP Control at Week 8 LOCF
percentage of participantsCore Period: LCI699 0.25 mg QDCore Period: LCI699 0.5 mg QDCore Period: LCI699 1.0 mg QDCore Period: LCI699 0.5 mg BIDCore Period: Eplerenone 50 mg BIDCore Period: Placebo
MSDBP Response39.134.150.034.448.827.6
MSDBP Control32.629.441.929.245.218.4
SecondaryCore Period: Percentage of Participants With a MSSBP Response and MSSBP Control at Week 8 LOCF

MSSBP response was defined as the percentage of participants with a MSSBP \<140 mmHg or a \>=20 mmHg reduction from baseline reduction from baseline. MSSBP control was defined as the percentage of participants with a MSSBP \<140 mmHg.

Time frame:
Baseline, Week 8
Reported as:
Number · percentage of participants
Core Period: Percentage of Participants With a MSSBP Response and MSSBP Control at Week 8 LOCF
percentage of participantsCore Period: LCI699 0.25 mg QDCore Period: LCI699 0.5 mg QDCore Period: LCI699 1.0 mg QDCore Period: LCI699 0.5 mg BIDCore Period: Eplerenone 50 mg BIDCore Period: Placebo
MSSBP Response39.137.648.834.452.417.1
MSSBP Control31.527.140.725.044.015.8
SecondaryCore Period: Change From Baseline in Plasma Cortisol Levels by Adrenocorticotropic Hormone (ACTH) Stimulation Test

The ACTH stimulation cortisol test was a standard procedure to measure the ability of adrenal cortex to respond to exogenous ACTH and directly assess the adrenal reserve. Serum cortisol concentrations at 1 hour after injection were measured to assess the maximum stimulated cortisol level achieved. Potential adrenal suppression was indicated if the serum cortisol concentration was \<500 nanomoles per liter (nmol/L) at 1 hour after the injection.

Time frame:
Baseline, 1 hour post-dose at Week 8
Reported as:
Mean · nanomoles per liter (nmol/L)
Core Period: Change From Baseline in Plasma Cortisol Levels by Adrenocorticotropic Hormone (ACTH) Stimulation Test
nanomoles per liter (nmol/L)Core Period: LCI699 0.25 mg QDCore Period: LCI699 0.5 mg QDCore Period: LCI699 1.0 mg QDCore Period: LCI699 0.5 mg BIDCore Period: Eplerenone 50 mg BIDCore Period: Placebo
Core Period: Change From Baseline in Plasma Cortisol Levels by Adrenocorticotropic Hormone (ACTH) Stimulation Test729.20 ± 123.753692.74 ± 117.645604.46 ± 125.017609.21 ± 107.923802.32 ± 134.497822.65 ± 116.041
SecondaryWithdrawal Period: Change From Week 8 to Week 9 in MSDBP at Week 9, as Measured by OBP

Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSDBP was calculated comparing the Week 9 readings to the readings taken at Week 8 (Baseline). The change from Week 8 to week 9 in MSDBP was analyzed using an ANCOVA with treatment and region as factors and Week 8 MSDBP level as a covariate.

Time frame:
From Week 8 to Week 9
Reported as:
Least squares mean · mm Hg
Withdrawal Period: Change From Week 8 to Week 9 in MSDBP at Week 9, as Measured by OBP
mm HgWithdrawal Period: LCI699 0.25 mg QDWithdrawal Period: LCI699 0.25 mg QD PlaceboWithdrawal Period: LCI699 0.5 mg QDWithdrawal Period: LCI699 0.5 mg QD PlaceboWithdrawal Period: LCI699 1.0 mg QDWithdrawal Period: LCI699 1.0 mg QD PlaceboWithdrawal Period: LCI699 0.5 mg BIDWithdrawal Period: LCI699 0.5 mg BID PlaceboWithdrawal Period: Eplerenone 50 mg BIDWithdrawal Period: Eplerenone 50 mg BID PlaceboWithdrawal Period: Placebo
Withdrawal Period: Change From Week 8 to Week 9 in MSDBP at Week 9, as Measured by OBP0.5 ± 0.990.5 ± 1.081.6 ± 1.01-0.2 ± 1.09-0.5 ± 1.032.5 ± 1.111.3 ± 1.001.3 ± 1.02-1.2 ± 1.060.4 ± 1.111.6 ± 0.83
SecondaryWithdrawal Period: Change From Week 8 to Week 9 in MSSBP at Week 9 as Measured by OBP

Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSSBP was calculated comparing the Week 9 readings to the readings taken at Week 8 (Baseline). The change from Week 8 to week 9 in MSSBP was analyzed using an ANCOVA with treatment and region as factors and Week 8 MSSBP level as a covariate.

Time frame:
From Week 8 to Week 9
Reported as:
Least squares mean · mm Hg
Withdrawal Period: Change From Week 8 to Week 9 in MSSBP at Week 9 as Measured by OBP
mm HgWithdrawal Period: LCI699 0.25 mg QDWithdrawal Period: LCI699 0.25 mg QD PlaceboWithdrawal Period: LCI699 0.5 mg QDWithdrawal Period: LCI699 0.5 mg QD PlaceboWithdrawal Period: LCI699 1.0 mg QDWithdrawal Period: LCI699 1.0 mg QD PlaceboWithdrawal Period: LCI699 0.5 mg BIDWithdrawal Period: LCI699 0.5 mg BID PlaceboWithdrawal Period: Eplerenone 50 mg BIDWithdrawal Period: Eplerenone 50 mg BID PlaceboWithdrawal Period: Placebo
Withdrawal Period: Change From Week 8 to Week 9 in MSSBP at Week 9 as Measured by OBP0.3 ± 1.663.3 ± 1.800.5 ± 1.692.5 ± 1.820.4 ± 1.725.3 ± 1.851.6 ± 1.684.4 ± 1.69-1.5 ± 1.792.7 ± 1.861.8 ± 1.39

Adverse events

Collected over AEs: From start of the study drug treatment up to 9 weeks; SAE: From signing of the informed consent up to 9 weeks. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Core Period: LCI699 0.25 mg QD0/92 (0%)1/92 (1.1%)22/92 (23.9%)
Core Period: LCI699 0.5 mg QD0/87 (0%)0/87 (0%)22/87 (25.3%)
Core Period: LCI699 1.0 mg QD0/87 (0%)0/87 (0%)24/87 (27.6%)
Core Period: LCI699 0.5 mg BID0/97 (0%)0/97 (0%)27/97 (27.8%)
Core Period: Eplerenone 50 mg BID0/84 (0%)0/84 (0%)26/84 (31%)
Core Period: Placebo0/76 (0%)1/76 (1.3%)23/76 (30.3%)
Withdrawal Period: LCI699 0.25 mg QD0/46 (0%)0/46 (0%)2/46 (4.3%)
Withdrawal Period: LCI699 0.25 mg QD Placebo0/38 (0%)0/38 (0%)1/38 (2.6%)
Withdrawal Period: LCI699 0.5 mg QD0/44 (0%)0/44 (0%)1/44 (2.3%)
Withdrawal Period: LCI699 0.5 mg QD Placebo0/37 (0%)0/37 (0%)0/37 (0%)
Withdrawal Period: LCI699 1.0 mg QD0/41 (0%)0/41 (0%)3/41 (7.3%)
Withdrawal Period: LCI699 1.0 mg QD Placebo0/37 (0%)0/37 (0%)5/37 (13.5%)
Withdrawal Period: LCI699 0.5 mg BID0/45 (0%)0/45 (0%)4/45 (8.9%)
Withdrawal Period: LCI699 0.5 mg BID Placebo0/45 (0%)0/45 (0%)3/45 (6.7%)
Withdrawal Period: Eplerenone 50 mg BID0/39 (0%)0/39 (0%)2/39 (5.1%)
Withdrawal Period: Eplerenone 50 mg BID Placebo0/36 (0%)0/36 (0%)0/36 (0%)
Withdrawal Period: Placebo0/66 (0%)0/66 (0%)3/66 (4.5%)
Most frequent serious events
Most frequent serious events
EventCore Period: LCI699 0.25 mg QDCore Period: LCI699 0.5 mg QDCore Period: LCI699 1.0 mg QDCore Period: LCI699 0.5 mg BIDCore Period: Eplerenone 50 mg BIDCore Period: PlaceboWithdrawal Period: LCI699 0.25 mg QDWithdrawal Period: LCI699 0.25 mg QD PlaceboWithdrawal Period: LCI699 0.5 mg QDWithdrawal Period: LCI699 0.5 mg QD PlaceboWithdrawal Period: LCI699 1.0 mg QDWithdrawal Period: LCI699 1.0 mg QD PlaceboWithdrawal Period: LCI699 0.5 mg BIDWithdrawal Period: LCI699 0.5 mg BID PlaceboWithdrawal Period: Eplerenone 50 mg BIDWithdrawal Period: Eplerenone 50 mg BID PlaceboWithdrawal Period: Placebo
Abdominal painGastrointestinal disorders0/920/870/870/970/841/760/460/380/440/370/410/370/450/450/390/360/66
Retinal vein occlusionEye disorders1/920/870/870/970/840/760/460/380/440/370/410/370/450/450/390/360/66
Most frequent other events
Showing 10 of 127
Most frequent other events
EventCore Period: LCI699 0.25 mg QDCore Period: LCI699 0.5 mg QDCore Period: LCI699 1.0 mg QDCore Period: LCI699 0.5 mg BIDCore Period: Eplerenone 50 mg BIDCore Period: PlaceboWithdrawal Period: LCI699 0.25 mg QDWithdrawal Period: LCI699 0.25 mg QD PlaceboWithdrawal Period: LCI699 0.5 mg QDWithdrawal Period: LCI699 0.5 mg QD PlaceboWithdrawal Period: LCI699 1.0 mg QDWithdrawal Period: LCI699 1.0 mg QD PlaceboWithdrawal Period: LCI699 0.5 mg BIDWithdrawal Period: LCI699 0.5 mg BID PlaceboWithdrawal Period: Eplerenone 50 mg BIDWithdrawal Period: Eplerenone 50 mg BID PlaceboWithdrawal Period: Placebo
HeadacheNervous system disorders1/924/871/872/973/8410/760/460/380/440/370/411/370/451/450/390/360/66
DizzinessNervous system disorders0/920/872/875/971/840/760/460/380/440/370/410/370/450/450/390/360/66
NasopharyngitisInfections and infestations1/922/873/871/974/843/760/460/380/440/370/410/371/451/450/390/360/66
Abdominal pain lowerGastrointestinal disorders0/920/870/870/970/840/760/460/380/440/370/411/370/450/450/390/360/66
Joint sprainInjury, poisoning and procedural complications2/920/871/870/970/841/760/460/380/440/370/411/370/450/450/390/360/66
MyalgiaMusculoskeletal and connective tissue disorders0/920/870/870/971/840/760/460/380/440/370/411/370/450/450/390/360/66
SyncopeNervous system disorders0/920/870/870/970/840/760/460/380/440/370/411/370/450/450/390/360/66
PalpitationsCardiac disorders1/921/870/870/971/842/760/460/380/440/370/410/370/450/450/390/360/66
DiarrhoeaGastrointestinal disorders2/921/870/870/970/842/760/460/380/440/370/410/370/450/450/390/360/66
NauseaGastrointestinal disorders1/920/871/871/970/842/760/460/380/440/370/410/370/450/450/390/360/66

Baseline characteristics

Full Analysis Set (FAS) population included all randomized participants or participants that met the inclusion criteria as described in study documentation protocol excluding misrandomized participants or participants with protocol violations.

Age, Continuous
Age, Continuous(years)Core Period: LCI699 0.25 mg QDCore Period: LCI699 0.5 mg QDCore Period: LCI699 1.0 mg QDCore Period: LCI699 0.5 mg BIDCore Period: Eplerenone 50 mg BIDCore Period: PlaceboTotal
Mean53.9 ± 10.554.8 ± 7.854.5 ± 9.754.4 ± 10.855.3 ± 9.153.9 ± 8.754.5 ± 9.50
Sex: Female, Male
Sex: Female, Male(Participants)Core Period: LCI699 0.25 mg QDCore Period: LCI699 0.5 mg QDCore Period: LCI699 1.0 mg QDCore Period: LCI699 0.5 mg BIDCore Period: Eplerenone 50 mg BIDCore Period: PlaceboTotal
Female292931332831181
Male635855635646341
Blood Pressure
Blood Pressure(millimeters of mercury (mm Hg))Core Period: LCI699 0.25 mg QDCore Period: LCI699 0.5 mg QDCore Period: LCI699 1.0 mg QDCore Period: LCI699 0.5 mg BIDCore Period: Eplerenone 50 mg BIDCore Period: PlaceboTotal
Clinic Systolic Blood Pressure (SBP)157.72 ± 12.163157.04 ± 11.580159.24 ± 10.415158.50 ± 11.028158.20 ± 10.954156.69 ± 10.121157.93 ± 11.074
Clinic Diastolic Blood pressure (DBP)100.43 ± 3.88499.94 ± 3.314100.03 ± 3.580100.21 ± 3.450100.39 ± 3.607100.54 ± 3.814100.25 ± 3.599
24-hour Ambulatory SBP141.97 ± 11.167140.08 ± 13.502143.85 ± 11.613142.20 ± 11.079143.30 ± 13.989142.07 ± 13.150142.25 ± 12.405
24-hour Ambulatory DBP90.13 ± 8.89389.33 ± 8.20891.38 ± 7.99890.81 ± 8.26091.14 ± 8.86190.11 ± 10.43990.49 ± 8.744
08

Study locations

1 site
  • Novartis Pharmaceuticals
    East Hanover, New Jersey, United States
09

References and documents

Publications

  • Schumacher CD, Steele RE, Brunner HR. Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. J Hypertens. 2013 Oct;31(10):2085-93. doi: 10.1097/HJH.0b013e328363570c. PubMed 24107737 ↗
  • Calhoun DA, White WB, Krum H, Guo W, Bermann G, Trapani A, Lefkowitz MP, Menard J. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation. 2011 Nov 1;124(18):1945-55. doi: 10.1161/CIRCULATIONAHA.111.029892. Epub 2011 Oct 10. PubMed 21986283 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2008 to primary completion in Jul 2009, 9 months.

Results were first posted in Jul 2021, 12 years after primary completion. A results delay was requested in May 2012.

Of 16 phase 2 interventional studies under Essential Hypertension, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2008
First posted
Sep 25, 2008
StartActual
Sep 11, 2008
Primary completionActual
Jul 2, 2009
CompletionActual
Jul 2, 2009
Results delay requested
May 31, 2012
Results first posted
Jul 6, 2021
Last update
Jul 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00758524
Responsible party
Sponsor
First posted
Sep 25, 2008
Start date
Sep 11, 2008
Primary completion
Jul 2, 2009
Completion
Jul 2, 2009
Results posted
Jul 6, 2021
Last update
Jul 6, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osilodrostat

Start the discussion